Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

FULGENT THERAPEUTICS, LLC.

NPI: 1174964738 · EL MONTE, CA 91731 · Clinical Medical Laboratory · NPI assigned 07/11/2013

Billing Flags · Automated signals — not evidence of fraud
Entity Proliferation

Authorized official KIM, PAUL controls 11+ related entities in our dataset. Read more

$84.90M
Total Medicaid Paid
2,346,002
Total Claims
1,672,728
Beneficiaries
33
Codes Billed
2018-10
First Month
2024-07
Last Month

Provider Details

Authorized OfficialKIM, PAUL (CFO)
NPI Enumeration Date07/11/2013

Related Entities

Other providers sharing the same authorized official: KIM, PAUL

ProviderCityStateTotal Paid
FULGENT THERAPEUTICS, LLC. EL MONTE CA $1.56M
PAUL H. KIM M.D., INC., A PROFESSIONAL CORPORATION TORRANCE CA $339K
CAL CITY URGENT CARE CALIFORNIA CITY CA $227K
BRADSHAW OPTOMETRY CORP SACRAMENTO CA $176K
PAUL J KIM MD INC TUSTIN CA $157K
DR. P.KIM PODIATRY, P.C. BROOKLYN NY $104K
BRADSHAW OPTOMETRY ELK GROVE CA $80K
GRACE HEMATOLOGY AND ONCOLOGY FLETCHER NC $36K
THINKNETIC MEDICAL CORPORATION SAN BERNARDINO CA $33K
PAUL E KIM MD INC SAN DIEGO CA $11K
SUN CITY OPTOMETRY A PROFESSIONAL CORPORATION MENIFEE CA $685.24

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 12 $16K
2019 47 $45K
2020 236,650 $15.51M
2021 1,230,348 $40.44M
2022 865,367 $28.33M
2023 12,180 $492K
2024 1,398 $73K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 1,237,212 888,342 $66.13M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 704,253 501,282 $7.52M
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 330,778 224,376 $5.53M
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B 58,236 45,229 $5.23M
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) 9,573 7,647 $249K
81479 Unlisted molecular pathology procedure 706 659 $91K
81406 556 540 $61K
81329 614 601 $22K
81222 532 518 $19K
0003A 608 607 $13K
0001A 852 851 $12K
0002A 699 699 $10K
0013A 394 394 $9K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 130 124 $5K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 30 30 $2K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc 26 26 $1K
0012A 153 153 $853.63
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 48 48 $467.55
0011A 138 138 $177.58
81361 39 39 $97.90
81257 38 38 $57.26
0031A 29 29 $40.59
81243 39 39 $31.94
81255 39 39 $28.82
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine 14 14 $27.50
81200 39 39 $26.46
81251 39 39 $26.46
81330 17 17 $26.32
81209 39 39 $22.02
81260 39 39 $22.02
81290 39 39 $22.02
81242 39 39 $20.50
81443 15 15 $0.00